Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Intuitive Surgical, Inc. (ISRG - Analyst Report) revealed that its da Vinci Fluorescence Imaging Vision System, well known as Firefly, has received FDA 510(k) clearance for use in gallbladder surgery.

The clearance means surgeons would now be able to identify the biliary duct with the help of the Firefly Imaging system properly for laparoscopic gallbladder removal surgeries. While performing surgeries, there is a higher chance of mistakenly identifying the cystic duct as bile duct leading to injuries due to clipping and division of the common duct.

However, Firefly Fluorescence Imaging Vision System would help surgeons use a specialized video camera to view real-time imaging of bile ducts (cystic duct, common bile duct and common hepatic duct).

Further, it will be able to identify blood flowing in vessels and tissue during minimally invasive surgical procedures. While using the Firefly camera, tissue with blood appears green and the same without blood appears gray.

Intuitive Surgical launched Firefly in 2011 for use with the da Vinci Si Surgical System in the U.S. and Europe. The system combines a fluorescent dye with a specialized camera, endoscope and laser-based illuminator to allow surgeons to identify vasculature in three dimensions beneath tissue surfaces.

ISRG reported earnings per share of $3.90 in the second quarter of 2013, missing the Zacks Consensus Estimate of $4.05 per share but exceeded the year-ago level of $3.75 per share. The company reported revenues of $579 million for the second quarter, up 8% year over year and trailed the Zacks Consensus Estimate of $596 million.

Intuitive Surgical significantly lowered its 2013 guidance based on the company’s dismal performance. Due to soft capital sales of the da Vinci system, the company lowered its revenue expectation from flat to 7% for 2013. Previously, ISRG had provided its sales growth guidance in the range of 16% to 19% for 2013. Operating income is forecast in a band of 37% to 38% of sales (earlier 38% to 39%) for 2013.

Currently, ISRG retains a Zacks Rank #3 (Hold). Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. (CYNO - Snapshot Report), Delcath Systems, Inc. (DCTH - Snapshot Report), and Echo Therapeutics, Inc. (ECTE - Snapshot Report). All of them carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%